Literature DB >> 25164527

Diagnostic criteria for Huntington's disease based on natural history.

Ralf Reilmann1, Blair R Leavitt, Christopher A Ross.   

Abstract

Huntington's disease (HD) is currently diagnosed based on the presence of motor signs indicating 99% "diagnostic confidence" for HD. Recent advances in the understanding of HD natural history and neurobiology indicate that disease-related brain changes begin at least 12 to 15 years before the formal diagnosis based on motor onset. Furthermore, subtle motor dysfunction, cognitive changes, and behavioral alterations are often seen before diagnosis made according to the current criteria. As disease-modifying treatments are developed, likely beginning therapy early will be desirable. We therefore suggest that expanded diagnostic criteria for HD should be adapted to better reflect the natural history of the disease, to enable the conduct of clinical trials in premanifest subjects targeting prevention of neurodegeneration, and to facilitate earlier symptomatic treatment. We propose a new set of criteria for HD diagnostic categories in the International Classification of Diseases that reflect our current understanding of HD natural history and pathogenesis. Based on defined criteria, for example, the Diagnostic Confidence Level and the Total Functional Capacity scales of the Unified Huntington's Disease Rating Scale, HD should be divided in the categories "genetically confirmed" with the subcategories "presymptomatic," "prodromal," and "manifest" and "not genetically confirmed" subdivided into "clinically at risk," "clinically prodromal," and "clinically manifest."
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Huntington's disease; care; chorea; clinical trials; diagnosis; diagnostic criteria; extrapyramidal; manifest HD; premanifest HD; presymptomatic HD; prodromal HD

Mesh:

Year:  2014        PMID: 25164527     DOI: 10.1002/mds.26011

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  49 in total

Review 1.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

2.  Penalized nonlinear mixed effects model to identify biomarkers that predict disease progression.

Authors:  Huaihou Chen; Donglin Zeng; Yuanjia Wang
Journal:  Biometrics       Date:  2017-02-09       Impact factor: 2.571

Review 3.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

4.  Comparison of mid-age-onset and late-onset Huntington's disease in Finnish patients.

Authors:  Jussi O T Sipilä; Tommi Kauko; Markku Päivärinta; Kari Majamaa
Journal:  J Neurol       Date:  2017-08-28       Impact factor: 4.849

5.  Through your eyes or mine? The neural correlates of mental state recognition in Huntington's disease.

Authors:  Clare M Eddy; Hugh E Rickards; Peter C Hansen
Journal:  Hum Brain Mapp       Date:  2017-12-17       Impact factor: 5.038

6.  The Confluence of Psychiatric Symptoms and Neurodegenerative Disease: Impact on Genetic Counseling.

Authors:  Jill S Goldman; Edward D Huey; Deborah Z Thorne
Journal:  J Genet Couns       Date:  2016-12-24       Impact factor: 2.537

7.  Factors Associated With End-of-Life Planning in Huntington Disease.

Authors:  Nancy R Downing; Siera Goodnight; Sena Chae; Joel S Perlmutter; Michael McCormack; Elizabeth Hahn; Stacey K Barton; Noelle Carlozzi
Journal:  Am J Hosp Palliat Care       Date:  2017-06-28       Impact factor: 2.500

Review 8.  Juvenile Huntington's Disease: Diagnostic and Treatment Considerations for the Psychiatrist.

Authors:  Joanna Quigley
Journal:  Curr Psychiatry Rep       Date:  2017-02       Impact factor: 5.285

Review 9.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

10.  Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?

Authors:  N E Carlozzi; S Schilling; A L Kratz; J S Paulsen; S Frank; J C Stout
Journal:  Qual Life Res       Date:  2018-06-16       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.